calcitonin gene-related peptide receptor antagonist

This page covers all calcitonin gene-related peptide receptor antagonist drugs tracked by Drug Landscape: marketed products and active clinical-stage compounds, targeting calcitonin gene-related peptide receptor, Calcitonin gene-related peptide type 1 receptor, calcitonin gene-related peptide receptor (CGRPR).

Targets

calcitonin gene-related peptide receptor · Calcitonin gene-related peptide type 1 receptor · calcitonin gene-related peptide receptor (CGRPR) · Calcitonin gene-related peptide receptor

Marketed (8)

• Rimegepant 75mg every other day dosing · Pfizer · Neuroscience · 798
  Rimegepant targets the calcitonin gene-related peptide receptor to treat migraines.
• Rimegepant for acute migraine treatment · Pfizer · Neuroscience
  Rimegepant targets the calcitonin gene-related peptide receptor to treat acute migraine.
• Rimegepant 25 MG · Pfizer · Neuroscience
• Zavzpret · Pfizer · Neuroscience
  Zavzpret blocks the action of calcitonin gene-related peptide, a molecule involved in pain transmission.
• Zavegepant 100mg immediate release tablet · Pfizer Inc.
• Rimegepant 75mg daily dosing · Pfizer · Neuroscience
  Rimegepant is a calcitonin gene-related peptide receptor antagonist that inhibits the release of pro-inflammatory peptides.
• Rimegepant 75mg Orally Disintegrating Tablets (ODT) · Pfizer · Neuroscience
  Rimegepant is a calcitonin gene-related peptide receptor antagonist.
• Nurtec Odt · Pfizer · Neuroscience
  Rimegepant blocks the calcitonin gene-related peptide receptor.

Phase 3 pipeline (1)

• Placebo-matching Ubrogepant · Allergan · Neurology
  Ubrogepant is a calcitonin gene-related peptide receptor antagonist.

Phase 2 pipeline (1)

• BHV-8000 · Biohaven Therapeutics Ltd. · Neurology
  BHV-8000 is a calcitonin gene-related peptide receptor antagonist.

Patent intelligence

• calcitonin gene related peptide receptor antagonist patent landscape — aggregated cliff calendar, attackable patents, originator estates